Security
Werewolf Therapeutics, Inc. Common Stock · HOWL
HOWLNASDAQCommon stockCurrentCIK 1785530Updated Nov 11, 2026
HOWL price & chart
Loading TradingView…
NASDAQ:HOWL on TradingView ↗About the company
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company has designed conditionally activated INDUKINETM molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. To learn more visit www.werewolftx.com.
In the news
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement ↗
Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 Million Private Placement ↗
Ra Capital sells $253,568 in Werewolf Therapeutics (NASDAQ:HOWL) stock ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 79,627,000Source | 140,036,000Source | 24,155,000Source | 92,566,000Source | 153,703,000Source | 58,022,000Source | 107,236,000Source | 177,600,000Source | 69,396,000Source | 126,929,000Source | 174,833,000Source | 160,245,000Source |
| Property, Plant and Equipment, NetUSD | 5,088,000Source | 6,765,000Source | 1,263,000Source | 5,490,000Source | 7,092,000Source | 4,290,000Source | 5,896,000Source | 7,529,000Source | 4,688,000Source | 6,322,000Source | 7,958,000Source | 8,988,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 65,711,000Source | 122,827,000Source | 21,987,000Source | 77,596,000Source | 135,303,000Source | 46,450,000Source | 92,042,000Source | 139,189,000Source | 57,050,000Source | 110,995,000Source | 134,343,000Source | 129,315,000Source |
| Assets, CurrentUSD | 68,173,000Source | 125,835,000Source | 22,892,000Source | 80,439,000Source | 138,788,000Source | 48,734,000Source | 94,457,000Source | 142,284,000Source | 58,586,000Source | 113,066,000Source | 138,370,000Source | 140,200,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 2,462,000Source | 2,544,000Source | 905,000Source | 2,843,000Source | 2,940,000Source | 2,284,000Source | 2,415,000Source | 2,320,000Source | 1,536,000Source | 2,071,000Source | 2,677,000Source | 3,957,000Source |
| Operating Lease, Right-of-Use AssetUSD | 5,422,000Source | 6,178,000Source | 0Source | 5,620,000Source | 6,347,000Source | 4,998,000Source | 5,813,000Source | 6,512,000Source | 5,216,000Source | 6,001,000Source | 6,888,000Source | 8,463,000Source |
| Other Assets, NoncurrentUSD | 46,000Source | 42,000Source | 0Source | 122,000Source | 265,000Source | 0Source | 179,000Source | 248,000Source | 5,000Source | 320,000Source | 594,000Source | 1,380,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 50,013,000Source | 50,657,000Source | 7,863,000Source | 51,102,000Source | 49,685,000Source | 45,820,000Source | 49,929,000Source | 60,013,000Source | 44,591,000Source | 53,539,000Source | 63,459,000Source | 37,908,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 4,000Source | 5,000Source | 5,000Source | 4,000Source | 5,000Source | 5,000Source | 4,000Source | 5,000Source | 5,000Source | 4,000Source | 3,000Source |
| Additional Paid in CapitalUSD | 496,638,000Source | 483,563,000Source | 501,559,000Source | 492,118,000Source | 481,529,000Source | 501,139,000Source | 489,979,000Source | 477,849,000Source | 500,210,000Source | 487,973,000Source | 455,443,000Source | 429,039,000Source |
| Retained Earnings (Accumulated Deficit)USD | -467,029,000Source | -394,188,000Source | -485,272,000Source | -450,659,000Source | -377,515,000Source | -488,942,000Source | -432,677,000Source | -360,266,000Source | -475,410,000Source | -414,588,000Source | -344,073,000Source | -306,705,000Source |
| Stockholders' Equity Attributable to ParentUSD | 29,614,000Source | 89,379,000Source | 16,292,000Source | 41,464,000Source | 104,018,000Source | 12,202,000Source | 57,307,000Source | 117,587,000Source | 24,805,000Source | 73,390,000Source | 111,374,000Source | 122,337,000Source |
| Liabilities and EquityUSD | 79,627,000Source | 140,036,000Source | 24,155,000Source | 92,566,000Source | 153,703,000Source | 58,022,000Source | 107,236,000Source | 177,600,000Source | 69,396,000Source | 126,929,000Source | 174,833,000Source | 160,245,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 17,603,000Source | 12,464,000Source | 7,863,000Source | 15,171,000Source | 11,442,000Source | 38,519,000Source | 11,669,000Source | 21,214,000Source | 36,148,000Source | 15,180,000Source | 19,378,000Source | 23,989,000Source |
| Operating Lease, Liability, CurrentUSD | 1,504,000Source | 1,320,000Source | 0Source | 1,454,000Source | 1,274,000Source | 1,604,000Source | 1,412,000Source | 1,236,000Source | 1,751,000Source | 1,557,000Source | 1,608,000Source | 2,084,000Source |
| Accounts Payable, CurrentUSD | 1,078,000Source | 1,240,000Source | 1,939,000Source | 2,774,000Source | 1,467,000Source | 3,569,000Source | 986,000Source | 1,594,000Source | 754,000Source | 3,035,000Source | 1,336,000Source | 1,221,000Source |
| Operating Lease, Liability, NoncurrentUSD | 8,140,000Source | 9,841,000Source | 0Source | 8,587,000Source | 10,239,000Source | 7,216,000Source | 9,017,000Source | 10,620,000Source | 7,684,000Source | 9,435,000Source | 10,992,000Source | 12,600,000Source |
| Other Liabilities, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 191,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 9,021,000Source | 9,904,000Source | 5,924,000Source | 8,543,000Source | 8,701,000Source | 4,515,000Source | 9,271,000Source | 6,215,000Source | 5,407,000Source | 10,588,000Source | 8,860,000Source | 14,152,000Source |
| Dividends PayableUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Long-term DebtUSD | 32,085,000Source | 32,085,000Source | — | 32,085,000Source | 32,085,000Source | 32,085,000Source | 32,085,000Source | 40,000,000Source | 32,085,000Source | 32,085,000Source | 40,000,000Source | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 929,000Source | 2,006,000Source | 6,245,000Source | 8,826,000Source | 8,008,000Source | 7,400,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -10,597,000Source | -18,948,000Source | -60,292,000Source | -56,188,000Source | -32,612,000Source | -40,596,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 0Source | -254,000Source | -769,000Source | -3,611,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 0Source | 0Source | 254,000Source | 769,000Source | 3,611,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 6,028,000Source | 13,080,000Source | 58,429,000Source | 15,906,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -10,597,000Source | -18,948,000Source | -54,264,000Source | -43,362,000Source | 25,048,000Source | -28,301,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 66,609,000Source | 124,043,000Source | 21,987,000Source | 78,491,000Source | 47,354,000Source | 93,267,000Source | 57,951,000Source | 112,215,000Source | 155,577,000Source | 130,529,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 773,000Source | 773,000Source | 3,133,000Source | 3,358,000Source | 2,556,000Source | — |
| Additional Financial Items | ||||||||||||
| Accretion ExpenseUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Share-based Payment Arrangement, ExpenseUSD | — | — | 1,233,000Source | 2,011,000Source | 419,000Source | 1,793,000Source | 929,000Source | 2,006,000Source | 6,245,000Source | 8,826,000Source | 8,008,000Source | 7,400,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | — | — | — | — | — | — | — | 0Source | 60,000Source | 203,000Source |
| DepreciationUSD | — | — | — | — | — | — | 398,000Source | 426,000Source | 1,634,000Source | 1,814,000Source | 1,764,000Source | 1,104,000Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | — | — | — | — | 674,000Source | 171,000Source | 2,070,000Source | 1,621,000Source | — | — |
| Dividends PayableUSD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -7,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | 0Source | 0Source | -3,354,000Source | 0Source | — | — | 0Source | -553,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | 4,092,000Source | 4,596,000Source | 7,680,000Source | 4,399,000Source | 5,090,000Source | 4,871,000Source | 15,847,000Source | 19,045,000Source | 18,670,000Source | 18,696,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| InterestExpenseNonoperatingUSD | — | — | 1,341,000Source | 1,244,000Source | 475,000Source | 1,301,000Source | 1,368,000Source | 1,263,000Source | 5,274,000Source | 4,656,000Source | — | — |
| Investment Income, InterestUSD | — | — | 697,000Source | 1,598,000Source | 277,000Source | 850,000Source | 433,000Source | 997,000Source | 3,108,000Source | 6,673,000Source | 7,416,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,370,000Source | -16,673,000Source | 3,670,000Source | -17,982,000Source | -13,532,000Source | -18,089,000Source | -60,822,000Source | -70,515,000Source | -37,368,000Source | -53,810,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -16,370,000Source | -16,673,000Source | — | -17,982,000Source | -13,532,000Source | -18,089,000Source | -60,822,000Source | -70,515,000Source | — | -53,810,000Source |
| Nonoperating Income (Expense)USD | — | — | -644,000Source | 451,000Source | -3,488,000Source | -440,000Source | -261,000Source | -98,000Source | -145,000Source | 3,079,000Source | 3,135,000Source | 2,246,000Source |
| Operating ExpensesUSD | — | — | 15,726,000Source | 17,124,000Source | 13,842,000Source | 17,542,000Source | 13,271,000Source | 17,991,000Source | 60,677,000Source | 75,479,000Source | 60,446,000Source | 72,457,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 97,000Source | 64,000Source | 11,000Source | 674,000Source | 168,000Source | 2,021,000Source | 1,615,000Source | -1,142,000Source | — |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 88,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 0Source | 5,939,000Source | 23,576,000Source | 18,329,000Source | 16,191,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 0Source | 0Source | 35,000Source | 7,000Source | 254,000Source |
| Gain (Loss) on Termination of Lease | — | — | — | — | —Source | — | — | — | — | — | — | — |
| Restructuring Costs | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -15,726,000Source | -17,124,000Source | 7,158,000Source | -17,542,000Source | -13,271,000Source | -17,991,000Source | -60,677,000Source | -73,594,000Source | -40,503,000Source | -56,056,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 97,000Source | 64,000Source | 11,000Source | 674,000Source | 168,000Source | 2,021,000Source | 1,615,000Source | -1,142,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -16,370,000Source | -16,673,000Source | 3,670,000Source | -17,982,000Source | -13,532,000Source | -18,089,000Source | -60,822,000Source | -70,515,000Source | -37,368,000Source | -53,810,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.36Source | -0.38Source | 0.08Source | -0.4Source | -0.28Source | -0.4Source | -1.32Source | -1.63Source | -1.05Source | -1.86Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.36Source | -0.38Source | 0.08Source | -0.4Source | -0.28Source | -0.4Source | -1.33Source | -1.63Source | -1.05Source | -1.86Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 45,804,042Source | 43,704,836Source | 48,597,534Source | 44,981,746Source | 48,596,817Source | 44,827,159Source | 46,018,888Source | 43,332,088Source | 35,646,572Source | 28,864,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 45,804,042Source | 43,704,836Source | 48,597,534Source | 44,981,746Source | 49,388,181Source | 44,827,159Source | 46,810,252Source | 43,859,664Source | 35,646,572Source | 28,864,000Source |
| Interest Expense (non-operating)USD | — | — | 1,341,000Source | 1,244,000Source | 475,000Source | 1,301,000Source | 1,368,000Source | 1,263,000Source | 5,274,000Source | 4,656,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 4,092,000Source | 4,596,000Source | 7,680,000Source | 4,399,000Source | 5,090,000Source | 4,871,000Source | 15,847,000Source | 19,045,000Source | 18,670,000Source | 18,696,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 3,139,000Source | — |
| Interest Expense, DebtUSD | — | — | 1,341,000Source | 1,244,000Source | 475,000Source | 1,301,000Source | 1,368,000Source | 1,263,000Source | 5,274,000Source | 3,311,000Source | — | — |
| Investment Income, InterestUSD | — | — | 697,000Source | 1,598,000Source | 277,000Source | 850,000Source | 433,000Source | 997,000Source | 3,108,000Source | 6,673,000Source | 7,416,000Source | — |
| Investment Income, NetUSD | — | — | — | — | — | — | — | — | — | — | — | 1,908,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -16,370,000Source | -16,673,000Source | — | -17,982,000Source | -13,532,000Source | -18,089,000Source | -60,822,000Source | -70,515,000Source | — | -53,810,000Source |
| Nonoperating Income (Expense)USD | — | — | -644,000Source | 451,000Source | -3,488,000Source | -440,000Source | -261,000Source | -98,000Source | -145,000Source | 3,079,000Source | 3,135,000Source | 2,246,000Source |
| Operating ExpensesUSD | — | — | 15,726,000Source | 17,124,000Source | 13,842,000Source | 17,542,000Source | 13,271,000Source | 17,991,000Source | 60,677,000Source | 75,479,000Source | 60,446,000Source | 72,457,000Source |
| Research and Development ExpenseUSD | — | — | 11,634,000Source | 12,528,000Source | 6,162,000Source | 13,143,000Source | 8,181,000Source | 13,120,000Source | 44,830,000Source | 56,434,000Source | 41,776,000Source | 53,761,000Source |
| Restructuring Costs | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
Offerings
Registration 333-299079
Filing attachments
ny20081588x4_ex107.htm · S-4/A · 2026-11-10
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) Werewolf Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registe…
Read attachment ↗ny20081588x4_ex99-1.htm · S-4/A · 2026-11-10
Exhibit 99.1 CONSENT OF PIPER SANDLER & CO. We hereby consent to the inclusion of our opinion letter to the Board of Directors of Werewolf Therapeutics, Inc. (the “Company”) as an Annex to the Proxy Statement/Prospectus relating to the proposed merger of the Company with Ambros Therapeutics, Inc. contained in Amendment No. 2 to the Registration Statement on Form S-4, as filed with the Securities and Exchange Commission, and to references to such opinion and the quotation or summarization of su…
Read attachment ↗d169523dex991.htm · 8-K · 2026-11-09
Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting In a Phase 1/1b clinical trial, WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the outpatient setting as monotherapy and in combination with pembrolizumab, with durable antitumor activity in patients with relapsed/refractory immunotherapy-sensitive solid tumors - ─────────────────────────────────────…
Read attachment ↗ny20081588x2_ex99-1.htm · S-4/A · 2026-10-26
Exhibit 99.1 CONSENT OF PIPER SANDLER & CO. We hereby consent to the inclusion of our opinion letter to the Board of Directors of Werewolf Therapeutics, Inc. (the “Company”) as an Annex to the Proxy Statement/Prospectus relating to the proposed merger of the Company with Ambros Therapeutics, Inc. contained in Amendment No. 1 to the Registration Statement on Form S-4, as filed with the Securities and Exchange Commission, and to references to such opinion and the quotation or summarization of su…
Read attachment ↗ny20081588x1_ex107.htm · S-4 · 2026-09-22
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) Werewolf Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registe…
Read attachment ↗ny20081588x1_ex99-1.htm · S-4 · 2026-09-22
Exhibit 99.1 CONSENT OF PIPER SANDLER & CO. We hereby consent to the inclusion of our opinion letter to the Board of Directors of Werewolf Therapeutics, Inc. (the “Company”) as an Annex to the Proxy Statement/Prospectus relating to the proposed merger of the Company with Ambros Therapeutics, Inc. contained in the Registration Statement on Form S-4, as filed with the Securities and Exchange Commission, and to references to such opinion and the quotation or summarization of such opinion in such …
Read attachment ↗